Stipple Bio to Receive Upfront Payment and Equity Investment Under Lilly Agreement
Story updates
09:06:26 PM UTC
SquawkNews
Eli Lilly NYSE:LLY has signed an oncology research collaboration and licensing agreement worth up to $5.9 billion with private biotechnology firm Stipple Bio, the companies said on Monday.